Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

NCT00074308 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage III Melanoma
Stage IV Melanoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: imatinib mesylate
BIOLOGICAL: bevacizumab
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)